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IMPORTANCE Regional variation in opioid usemay be attenuated when pharmaceutical-
sponsored trials include care that is often standardized by protocols. Understanding such
variation is important for global trials that sometimes include time to opioid use as an end
point.
OBJECTIVE To identify whether regional and country-level variation in opioid use exists
among prostate cancer clinical trials across the world.
DESIGN, SETTING, AND PARTICIPANTS International phase 3 randomized clinical trials with
patients with metastatic prostate cancer and initiation from January 1, 2008, or later were
identified through internal databases of the US Food and Drug Administration. Data of
patients in the intention-to-treat population from each trial were pooled. Descriptive and
regression analyses of the collected data were conducted from September 2018 to
February 2019.
EXPOSURES Cancer therapy.
MAIN OUTCOMES ANDMEASURES Opioid use data were from concomitantmedications
reported in the database for each trial. Logistic regressionmodels, descriptive statistics,
and χ2 tests were used to compare opioid use across world regions while adjusting for patient
age, presence of visceral disease, bony disease, and baseline Eastern Cooperative Oncology
Group Performance Status score and pain score.
RESULTS In total, 9670 patients (mean [SD] age of 69.2 [8.3] years) from 8 prostate cancer
clinical trials in 46 countries were included. Patients in Eastern Europe (adjusted odds ratio
[AOR], 0.19; 95% CI, 0.16-0.22) and Asia (AOR, 0.31; 95% CI, 0.25-0.38) were less likely to
use opioids compared with patients in North America. These findings held even when the
analysis was restricted to patients who reportedmoderate to high pain levels at baseline
(Eastern Europe: AOR, 0.16 [95% CI, 0.12-0.22]; Asia: AOR, 0.47 [95% CI, 0.29-0.79]).
Within North America, rates of opioid use were similar between the United States and Canada
(AOR, 1.13; 95% CI, 0.93-1.37).
CONCLUSIONS AND RELEVANCE This study found that, despite the clinical trial setting, opioid
use appeared to vary by world regions, suggesting that this variability should be considered
in international clinical trials.
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P
ain is a commonsymptom in cancer, particularlywhen
disease has metastasized to the bone.1 Undertreat-
ment of cancer pain has been described in previous
studies,2,3 and access to opioid analgesics varies around the
world,4-10 with poorer access reported in lower- and middle-
income countries.11,12
Only a small proportionofpatientswith cancerparticipate
inclinical trials,13andpatients inthesetrialsoftendiffer fromthe
generalpatientpopulationbothsociodemographically14-16and
clinically.17,18Furthermore, in industry-sponsoredtrialsofprod-
ucts seeking regulatory approval, some aspects of caremay be
standardizedbyprotocols.Thus,toourknowledge,whetherpre-
viouslydocumentedvariability inopioidanalgesicuse in clini-
cal practice also occurs in the clinical trial setting is unknown.
Thisvariability isanimportantconsiderationbecauseopioiduse
is associatedwithadverseeffects, anddelayofopioid initiation
canbeatrialendpoint,particularly inprostatecancer.19,20Given
that industry-sponsored trials are often global, understanding
thevariations inopioiduseamongpatientswithcancerenrolled






Administration (FDA)were used to identify the trials. The FDA
OncologyCenterofExcellenceapprovedtheconductof this ret-
rospective reviewofclinical trialdatahoused in theFDAclinical
trial repository.TheFDAproject leadand/or theCenter forDrug
EvaluationandResearchHumanSubjectProtectionliaisontothe
FDA institutional reviewboard determined that this studywas
consistentwitha“nothumansubject research”designationand
thus did not require institutional reviewboard approval.
Participants
Primary analyses of patients in the intention-to-treat popula-
tion were conducted. Patient data were pooled across trials.
Patient eligibility varied across the trials, but trial criteria con-
sistently excluded patients with Eastern Cooperative Oncol-
ogyGroup (ECOG)PerformanceStatus (PS) scores (range:0 [no
restrictionsonactivity] to5 [dead])above2orwithknownbrain
metastases. Trials also excluded patients with major labora-
tory result abnormalities, previousmalignantneoplasmsother
than nonmelanoma skin cancer within the past 5 years, and
severe cardiovascular disease. Inclusion or exclusion criteria
for baselinepain scores, thepresenceof bonemetastases, and
the use or nonuse of previous or concurrent therapies varied
dependingontrialobjectives.Noninvestigationalarmsalsovar-
ied across the trials, although all contained a backbone of an-
drogendeprivation therapy. These arms includedplaceboand
supportive therapies (n = 6), which generally included corti-
costeroids, and active agents that had previously been dem-
onstrated to prolong overall survival (n = 2).
Overall survival was a primary end point for all trials, al-
thoughsometrials also includedradiographicprogression-free
survival as a co–primary end point. Secondary end points var-
iedbytrial, althoughall trialsevaluatedtimetoprostate-specific
antigen progression. Opioid usewas a secondary end point for
3trialseitheronitsownoraspartofacompositeendpointevalu-
atingpain.Stratification factors for randomization likewisevar-
ied by trial, with 3 trials stratified by region and/or study site.
Several subpopulationswerealso considered in this analy-
sis. The first subgroup analysis included only patients with a
higher tumorburden, asdeterminedby theextentof bonydis-
ease. This information was available from 5 trials. High tu-
morburdenwasdefinedas6ormorebone lesions.This thresh-
old is supported by previous studies that have identified
improved survival for patients with fewer than 6 lesions.21,22
In addition, subgroup analyses were conducted that com-
paredpatientswithmoreadvanceddisease(enrolledinlater-line
postchemotherapy trials)withpatientswith less advanceddis-
easeand thosewithmoderate tohigh levels ofpainatbaseline.
Outcomes
Theoutcomeof interestwas theuse of opioids at anypoint be-
fore, during, or after the trial. In a sensitivity analysis, the out-
comeof interestwas limited toopioiduseduring the trial.Data
onopioidusewere captured through theconcomitantmedica-
tiondata sets submitted to theFDA.Drugs in thesedata sets are






were reviewedbyoneofus (L.A.M.).All other instancesof opi-
oidusewere retained, evenwhenan indication specific to can-
cerpainwasnotprovided.Long-termusewasnotconsidered in
this analysis; if apatientwas recordedashavingusedopioidsat
least 1 time, thiswas defined as opioid use.
Statistical Analysis
Global and regional variations inopioiduseweredefinedwith
descriptive statistics, χ2 tests, and binary logistic regression
models. In this exploratory study,noadjustmentwasmade for
multiple statistical testing. The primary logistic regression
model for geographic region as the independent variable was
Key Points
Question Do regional variations in opioid use exist in a controlled
clinical trial setting?
Findings In this study of 8 randomized clinical trials for prostate
cancer conducted in 46 countries involving 9670 participants,
fewer patients in Eastern Europe and Asia received opioids
compared with patients in North America, a pattern that persisted
even after adjustment for clinical and sociodemographic
characteristics. Within North America, opioid use was similar
between the United States and Canada.
Meaning This study suggests that global variability in opioid use
should be considered in international clinical trials using delay in
opioid initiation as a trial end point.
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adjusted for bonydisease (yes or no), baseline ECOGPS score,
patient age, baselinepain level (unknownormissing, less than
moderatepain, ormoderate tohighpain), andpresenceof vis-
ceraldisease (yesorno).Differences inopioiduse foreachcom-
parison are described using adjusted odds ratios (AORs). Be-
cause the instruments for evaluating pain varied across the
trials, existingcategorizationswereusedwhenavailable. If cat-
egorizations were not available, the higher end of the score
range was considered moderate to high.
Countries were classified as high income or not high in-
come according to the World Bank definition,23 and the dif-
ference inopioidusewas evaluatedon thebasis of country in-
comelevel.Asubgroupanalysisadjusting for theextentofbony
disease (≥6vs<6 lesions)wasconducted in the5trials forwhich
this information was available. In a sensitivity analysis, a
threshold of 10 lesionswas also considered, following the ap-
proach taken in a clinical trial.24 The primary model was re-
run with on-trial (rather than any) opioid use as the depen-
dentvariable aswell as in thepooledsafetypopulation (at least
1 dose of drug) rather than the intention-to-treat population
(with any and with on-trial opioid use).
For descriptive country-level analyses, countries with at
least 50 patients were included. All analyses were conducted
inR Studio, version 1.1.423 (RFoundation for Statistical Com-
puting). Descriptive and regression analyses of the collected
datawere conducted fromSeptember 2018 to February 2019.
Results
Patients
The combined total of the intention-to-treat population from
the 8 trials was 9687 patients. Patients who had protocol vio-
lation or unknown ECOG PS scores (n = 5) or who lacked in-
formationaboutbone involvement (n = 12)wereexcluded.The
analysis population consistedof 9670patients (mean [SD] age
of 69.2 [8.3] years) from 46 countries. The advanced disease
trials comprised 4502 patients (46.6%), and 2353 patients
(24.3%)hadmoderate tohigh levels of pain at baseline.Nearly
all patients (8786 [90.9%]) had bony disease, and most (9115
[94.3%]) had ECOG PS scores of 0 or 1.
Most patients (8367 [86.5%]) resided in high-income
countries. Recruitment was global, with just 2353 (24.3%) of
patients from North America (1661 [17.2%] from the United
States) (eTable in the Supplement). Patient characteristics
were broadly similar across the primary analysis population
and the subpopulations of interest. Higher (worse) ECOG PS
scores and opioid use were more common in patients with
moderate to high levels of pain at baseline (Table 1). The per-
centage of patients with moderate to high pain at baseline
was greatest in the Middle East and Africa at 34.6% and
Eastern Europe at 32.9% and was lowest in Asia at 17.6%
(Table 2).
Outcomes
Unadjusted Comparison of Opioid Use
More than half of the analysis population used opioids (4983
[51.5%]), and4877patients (50.4%)usedopioidswhileon trial.
Opioid use was less common in Asia (174 of 528 [33.0%]) and
Eastern Europe (367 of 1196 [30.7%]) compared with North
America (1391 of 2353 [59.1%]), Oceania (451 of 834 [54.1%]),
and Western Europe (2321 of 4140 [56.1%]). Across all re-
gions, opioid usewasmore common in patientswith high tu-
mor burden andmore advanced disease (Table 3).
Variationinopioidusewasseenacrosscountrieswithinare-




example, in Asia, opioid usewas higher in Korea (85 of 167 pa-
tients [50.9%]) thanJapan (35of 149patients [23.5%]). InWest-
ern Europe, rates of use ranged from 36.4% (20 of 55 patients)
inAustria to83.2%(114of 137patients) inNorway,withapproxi-
mately40%to60%ofpatients inmostWesternEuropeancoun-
triesusingopioids (medianof approximately 50%).Opioiduse
intheUnitedStatesandCanadawassimilar (989of1661patients
[59.5%] vs 402 of 692 patients [58.1%]).
Adjusted Comparison of Opioid Use
After adjustment forbone involvement, visceral disease, base-
line ECOG PS and pain categories, and age, patients in Asia
(AOR,0.31; 95%CI,0.25-0.38) andEasternEurope (AOR,0.19;
95% CI, 0.16-0.22) remained less likely to use opioids com-
pared with patients in North America (Table 5). Similar re-
sultswere foundwhen thedependentvariablewason-trialuse
rather than any opioid use. When the variation in North
America specifically was examined, no substantial differ-
ence was found between the United States and Canada after
adjustment for clinical anddemographic characteristics (AOR,
1.13;95%CI,0.93-1.37). Patients inhigh-incomecountrieswere
more likely to use opioids compared with those in not-high-
income countries (AOR, 5.29; 95% CI, 4.59-6.10).
Withadjustment for theextentofbonydisease rather than
presence or absence of bone involvement, the findings were
similar for bothAsia (AOR, 0.24; 95%CI, 0.18-0.30) and East-
ern Europe (AOR, 0.15; 95% CI, 0.12-0.19). Defining high dis-
ease burden as at least 10 lesions rather than at least 6 lesions
did not change the findings.When the analysiswas restricted
to patients with at least 6 bone lesions, the results were not
substantially changed for Asia (AOR, 0.23; 95% CI, 0.16-0.31)
or Eastern Europe (AOR, 0.14; 95% CI, 0.11-0.18) (Table 5).
Inanalyses restricted topatientswithmoderate tohigh lev-
els of pain at baseline, the results of regional variation were
consistent with those of the primary analytic population. Pa-
tients in Asia (AOR, 0.47; 95% CI, 0.29-0.79) and Eastern
Europe (AOR, 0.16; 95% CI, 0.12-0.22) used opioids less fre-
quently than those in North America.
Discussion
In thispooledanalysis of8different international clinical trials
inmetastatic prostate cancer, regional variations inopioiduse
were evident. Patients in Asian and Eastern European coun-
trieswere less likely to use opioids comparedwith patients in
North America. This disparity persisted after adjusting for
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clinical and demographic characteristics and was seen in pa-
tients with moderate to high pain levels. Possible explana-
tions for the disparity include local attitudes and practices as
well as lack of access to opioids and potential undertreat-
ment for patients in some cases.
Although higher percentages of patients in high-income
countriesusedopioidscomparedwiththose innot-high-income
countries,usevariedacrosshigh-incomecountries.These find-
ings of lower opioiduse in specific countries are generally con-
sistent with previous reports in nontrial settings. The Global



















Opioid use at any time 4983 (51.5) 2241 (60.3) 2937 (65.2) 2046 (39.6) 1646 (70.0)
Opioid use during trial 4877 (50.4) 2170 (58.4) 2854 (63.4) 2023 (39.1) 1616 (68.7)
Patient age, mean (SD), y 69.2 (8.3) 69.5 (8.6) 69.0 (8.1) 69.3 (8.6) 67.8 (8.2)
Bone involvement present
at baseline
8786 (90.9) 3715 (100.0) 4204 (93.4) 4582 (88.7) 2250 (95.6)
Visceral disease present
at baseline
1646 (17.0) 434 (11.7) 964 (21.4) 682 (13.2) 595 (25.3)
Baseline ECOG PS score
0 4667 (48.3) 1751 (47.1) 1484 (33.0) 3183 (61.6) 603 (25.6)
1 4448 (46.0) 1741 (46.9) 2553 (56.7) 1895 (36.7) 1440 (61.2)
2 555 (5.7) 223 (6.0) 465 (10.3) 90 (1.7) 310 (13.2)
Pain status at baseline
Not high or moderate 6934 (71.7) 2826 (76.1) 2695 (59.9) 4239 (82.0) 0 (0.0)
High or moderate 2353 (24.3) 764 (20.6) 1604 (35.6) 749 (14.5) 2353 (100.0)
Unknown or missing 383 (4.0) 125 (3.4) 203 (4.5) 180 (3.5) 0 (0.0)
Region
Asia 528 (5.5) 250 (6.7) 95 (2.1) 433 (8.4) 93 (4.0)
Eastern Europe 1196 (12.4) 498 (13.4) 393 (8.7) 803 (15.5) 394 (16.7)
Middle East and Africa 205 (2.1) 94 (2.5) 76 (1.7) 129 (2.5) 71 (3.0)
North America 2353 (24.3) 755 (20.3) 1179 (26.2) 1174 (22.7) 537 (22.8)
Oceania 834 (8.6) 252 (6.8) 348 (7.7) 486 (9.4) 179 (7.6)
South and Central
America
414 (4.3) 149 (4.0) 197 (4.4) 217 (4.2) 126 (5.4)
Western Europe 4140 (42.8) 1717 (46.2) 2214 (49.2) 1926 (37.3) 953 (40.5)
Recruited from
high-income country
8367 (86.5) 3194 (86.0) 4140 (92.0) 4227 (81.8) 1927 (81.9)
Abbreviation: ECOG PS, Eastern
Cooperative Oncology Group
Performance Status (score range: 0
[no restrictions on activity] to 5
[dead]).
Table 2. Regional Comparison of Patient Baseline Characteristics and Outcomes
Variable













America (n = 414)
Western Europe
(n = 4140)
Patient age, mean (SD), y 69.2 (8.1) 66.7 (8.2) 67.5 (9.0) 70.1 (8.8) 70.2 (8.4) 69.1 (8.1) 69.3 (8.0)
Bone involvement present 503 (95.3) 1142 (95.5) 195 (95.1) 2061 (87.6) 744 (89.2) 403 (97.3) 3738 (90.3)
Visceral disease present 96 (18.2) 244 (20.4) 47 (22.9) 419 (17.8) 128 (15.3) 85 (20.5) 627 (15.1)
Baseline ECOG PS score
0 299 (56.6) 415 (34.7) 99 (48.3) 1172 (49.8) 416 (49.9) 153 (37.0) 2113 (51.0)
1 198 (37.5) 713 (59.6) 97 (47.3) 1061 (45.1) 363 (43.5) 228 (55.1) 1788 (43.2)
2 31 (5.9) 68 (5.7) 9 (4.4) 120 (5.1) 55 (6.6) 33 (8.0) 239 (5.8)
Pain status at baseline
Not high or moderate 433 (82.0) 766 (64.0) 123 (60.0) 1774 (75.4) 638 (76.5) 248 (59.9) 2952 (71.3)
High or moderate 93 (17.6) 394 (32.9) 71 (34.6) 537 (22.8) 179 (21.5) 126 (30.4) 953 (23.0)
Unknown or missing 2 (0.4) 36 (3.0) 11 (5.4) 42 (1.8) 17 (2.0) 40 (9.7) 235 (5.7)
Residing in high-income
countriesa
375 (71.0) 501 (41.9) 77 (37.6) 2353 (100.0) 834 (100.0) 87 (21.0) 4140 (100.0)
Abbreviation: ECOG PS, Eastern Cooperative Oncology Group Performance Status (score range: 0 [no restrictions on activity] to 5 [dead]).
a PerWorld Bank definition.
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Disease (n = 4502)
Less Advanced
Disease (n = 5168)
Moderate to High
Pain Level at
Baseline (n = 2353)
Asia 174 (33.0) 91 (36.4) 64 (67.4) 110 (25.4) 64 (68.8)
Eastern Europe 367 (30.7) 169 (33.9) 185 (47.1) 182 (22.7) 182 (46.2)
Middle East or
Africa
97 (47.3) 51 (54.3) 45 (59.2) 52 (40.3) 39 (54.9)
North America 1391 (59.1) 519 (68.7) 824 (69.9) 567 (48.3) 439 (81.8)
Oceania 451 (54.1) 176 (69.8) 220 (63.2) 231 (47.5) 122 (68.2)
South or Central
America
182 (44.0) 80 (53.7) 98 (49.7) 84 (38.7) 71 (56.3)
Western Europe 2321 (56.1) 1155 (67.3) 1501 (67.8) 820 (42.6) 729 (76.5)
a Denominator for each cell is the
total number of patients within each
region.
Table 4. Country-Level Percentages of Opioid Usea
Country No. in Population
Any Opioid Use,
No. (%) Income Statusb
Asia
Japan 149 35 (23.5) High income
Korea 167 85 (50.9) High income
China 147 22 (15.0) Not high income
Eastern Europe
Czech Republic 98 54 (55.1) High income
Hungary 91 30 (33.0) High income
Poland 218 114 (52.3) High income
Slovakia 80 41 (51.3) High income
Romania 161 44 (27.3) Not high income
Russia 366 65 (17.8) Not high income
Ukraine 145 13 (9.0) Not high income
Middle East or Africa
Israel 77 36 (46.8) High income
South Africa 60 36 (60.0) Not high income
Turkey 52 17 (32.7) Not high income
North America
Canada 692 402 (58.1) High income
United States 1661 989 (59.5) High income
South and Central America
Brazil 198 103 (52.0) Not high income
Mexico 74 11 (14.9) Not high income
Western Europe
Austria 55 20 (36.4) High income
Belgium 288 160 (55.6) High income
Denmark 199 85 (42.7) High income
Finland 77 36 (46.8) High income
France 885 522 (59.0) High income
Germany 429 191 (44.5) High income
Italy 202 95 (47.0) High income
The Netherlands 176 85 (48.3) High income
Norway 137 114 (83.2) High income
Portugal 73 36 (49.3) High income
Spain 423 186 (44.0) High income
Sweden 215 132 (61.4) High income
United Kingdom 953 643 (67.5) High income
a To avoid small cell problems,
we analyzed data from only the
countries with at least 50 patients.
bPerWorld Bank definition.
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Opioid Policy Initiative survey in Asia found that opioid con-
sumption was highest in Korea, followed by Japan and then
China,8a finding thatwasalsoobserved in thepresentdata set.
Similarly, this study’s findingofcomparatively loweropioiduse
in Ukraine andRussia is consistentwith results of previous re-
search on country- and region-level opioid consumption.25
This study is unique in severalways. Previous researchon
disparities in global opioidusehas examined formulary avail-
ability and cost4or evaluateddata from the InternationalNar-
cotics Control Board.26These studies provide information on
country and regional issues, but they do not provide specific




across patients with cancer from a range of different coun-
tries within the clinical trial setting.
Strengths and Limitations
Astrengthof this study is theability toassesspatient-leveldata
in a setting that has been unexplored, despite the use of end
points involvingopioidsaswell as thepotential differencesbe-
tweenacontrolled trial settingandacommunitypractice.This
studyalsohas several limitations. First, some instancesof opi-
oid usemay have beenmissed if patients did not share infor-
mationwith studypersonnel; however, concomitantmedica-
tion data sets in trials typically seek to record all nontrial
medication use. In addition, opioids that were not classified
usingATCcodeswerenot captured, and theonly excluded in-
dications of opioid use were for pain prophylaxis associated
withprocedures. Second, attributingopioiduse to cancerpain
rather than to noncancer pain is challenging. A conservative
approach was taken by including all nonprophylactic or pro-
ceduralopioiduse.Third, an indicatorvariable formissingpain
dataatbaselinewasusedrather thanmultiple imputation.This
approach assumes that the missing data are missing at ran-
dom, which may not be verifiable. However, to date, simula-
tions have not shown that multiple imputation is superior to
simpler approaches, such as a missing indicator, for missing
baseline covariates.30
Conclusions
This study documented the variability in opioid analgesic
use across regions and countries in prostate cancer clinical
Table 5. Results of Logistic RegressionModels of Opioid Usea
Variable



















Asia 0.31 (0.25-0.38) 0.23 (0.16-0.31) 0.73 (0.46-1.18) 0.31 (0.24-0.40) 0.47 (0.29-0.79)
Eastern Europe 0.19 (0.16-0.22) 0.14 (0.11-0.18) 0.25 (0.19-0.32) 0.21 (0.17-0.26) 0.16 (0.12-0.22)
Middle East and
Africa
0.47 (0.34-0.63) 0.42 (0.27-0.67) 0.48 (0.29-0.80) 0.55 (0.38-0.81) 0.26 (0.15-0.44)
North America 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
Oceania 0.79 (0.67-0.93) 1.04 (0.75-1.43) 0.60 (0.46-0.78) 0.97 (0.78-1.20) 0.43 (0.29-0.64)
South and
Central America
0.39 (0.31-0.48) 0.35 (0.24-0.51) 0.34 (0.25-0.48) 0.50 (0.36-0.67) 0.25 (0.16-0.38)
Western Europe 0.84 (0.75-0.93) 0.85 (0.70-1.02) 0.88 (0.75-1.04) 0.76 (0.66-0.89) 0.71 (0.54-0.93)
Bone involvement
present (vs not)





2.60 (2.01-3.37) 1.77 (1.47-2.15) 2.29 (1.49-3.48)
Visceral disease
present (vs not)
0.94 (0.83-1.05) 0.86 (0.69-1.08) 0.85 (0.72-1.00) 0.97 (0.81-1.15) 0.95 (0.77-1.18)
Baseline ECOG PS score
0 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
1 1.98 (1.81-2.17) 2.06 (1.77-2.40) 2.05 (1.78-2.37) 1.54 (1.35-1.75) 1.88 (1.52-2.32)
2 4.06 (3.26-5.09) 3.91 (2.70-5.77) 3.73 (2.84-4.94) 2.34 (1.49-3.67) 3.24 (2.30-4.62)
Pain category at baseline
Not moderate or
high







2.38 (2.13-2.66) 2.71 (2.21-3.33) 2.79 (2.39-3.26) 1.58 (1.33-1.88) NA
Missing 0.96 (0.77-1.19) 1.27 (0.85-1.91) 0.96 (0.71-1.31) 0.91 (0.66-1.24) NA
Age (continuous) 0.98 (0.97-0.98) 0.97 (0.97-0.98) 0.97 (0.96-0.97) 0.98 (0.98-0.99) 0.99 (0.97-0.997)
Abbreviations: ECOG PS, Eastern
Cooperative Oncology Group
Performance Status (score range: 0
[no restrictions on activity] to 5
[dead]); NA, not applicable.
a Adjusted for the variables shown.
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trials, suggesting the existence of disparities in oncologic
pain management in the previously unexplored controlled
trial setting. Although patients in US trials demonstrated a
higher level of opioid use than those in several other regions,
opioid use appeared similar between the United States
and Canada. However, other regions had greater within-
region variability in opioid use. These findings suggest that
global variability in opioid use should be considered
for international clinical trials using delay in opioid initiation
as an end point or otherwise incorporating opioid use into
trial end points. If region is not a stratification factor, then
sponsors may wish to assess regional variability when ana-
lyzing these end points, depending on their countries of
recruitment.
ARTICLE INFORMATION
Accepted for Publication:May 27, 2019.
Published Online: September 12, 2019.
doi:10.1001/jamaoncol.2019.2971
Author Contributions:Dr Roydhouse had full
access to all of the data in the study and takes
responsibility for the integrity of the data and the
accuracy of the data analysis.
Concept and design: Roydhouse, Mishra-Kalyani,
Pazdur, Kluetz.
Acquisition, analysis, or interpretation of data:
Roydhouse, Suzman, Menapace, Sridhara,
Blumenthal, Beaver, Pazdur, Kluetz.
Drafting of the manuscript: Roydhouse,
Mishra-Kalyani, Beaver, Pazdur.
Critical revision of the manuscript for important
intellectual content: All authors.
Statistical analysis: Roydhouse, Mishra-Kalyani,
Sridhara, Pazdur.
Administrative, technical, or material support:
Sridhara, Blumenthal, Pazdur.
Supervision: Blumenthal, Beaver, Pazdur, Kluetz.
Other - Provided clinical expertise and interpretation
of data:Menapace.
Conflict of Interest Disclosures:None reported.
Disclaimer:Thispaperreflectstheviewsoftheauthors
and shouldnotbe construed to represent theviewsor
policies of theUSFoodandDrugAdministration.
REFERENCES
1. Kane CM, Hoskin P, Bennett MI. Cancer induced
bone pain.BMJ. 2015;350:h315. doi:10.1136/bmj.h315
2. Apolone G, Corli O, Caraceni A, et al; Cancer Pain
Outcome Research Study Group (CPOR SG)
Investigators. Pattern and quality of care of cancer
pain management. Results from the Cancer Pain
Outcome Research Study Group. Br J Cancer. 2009;
100(10):1566-1574. doi:10.1038/sj.bjc.6605053
3. Deandrea S, Montanari M, Moja L, Apolone G.
Prevalence of undertreatment in cancer pain.
A review of published literature. Ann Oncol. 2008;
19(12):1985-1991. doi:10.1093/annonc/mdn419
4. ChernyNI, Cleary J, ScholtenW,RadbruchL,
Torode J. TheGlobalOpioidPolicy Initiative (GOPI)
project to evaluate the availability andaccessibility of
opioids for themanagementof cancer pain inAfrica,
Asia, LatinAmerica and theCaribbean, and theMiddle
East: introduction andmethodology.AnnOncol.
2013;24(suppl 11):xi7-xi13. doi:10.1093/annonc/mdt498
5. Cleary J, Silbermann M, Scholten W, Radbruch L,
Torode J, ChernyNI. Formulary availability and
regulatorybarriers toaccessibilityofopioids forcancer
pain in theMiddleEast:a report fromtheGlobalOpioid
Policy Initiative (GOPI). Ann Oncol. 2013;24(suppl 11):
xi51-xi59. doi:10.1093/annonc/mdt503
6. Cleary J, De Lima L, Eisenchlas J, Radbruch L,
Torode J, Cherny NI. Formulary availability and
regulatory barriers to accessibility of opioids for
cancer pain in Latin America and the Caribbean:
a report from the Global Opioid Policy Initiative
(GOPI). Ann Oncol. 2013;24(suppl 11):xi41-xi50.
doi:10.1093/annonc/mdt502
7. Cleary J, SimhaN,Panieri A, et al. Formulary
availability and regulatorybarriers to accessibility
of opioids for cancer pain in India: a report fromthe
GlobalOpioidPolicy Initiative (GOPI).AnnOncol. 2013;
24(suppl 11):xi33-xi40. doi:10.1093/annonc/mdt501
8. Cleary J, Radbruch L, Torode J, Cherny NI.
Formulary availability and regulatory barriers to
accessibility of opioids for cancer pain in Asia:
a report from the Global Opioid Policy Initiative
(GOPI). Ann Oncol. 2013;24(suppl 11):xi24-xi32.
doi:10.1093/annonc/mdt500
9. Cleary J, Powell RA,MuneneG, et al. Formulary
availability and regulatorybarriers to accessibility of
opioids for cancer pain inAfrica: a report fromthe
GlobalOpioidPolicy Initiative (GOPI).AnnOncol. 2013;
24(suppl 11):xi14-xi23. doi:10.1093/annonc/mdt499
10. Cherny NI, Baselga J, de Conno F, Radbruch L.
Formulary availability and regulatory barriers to
accessibility of opioids for cancer pain in Europe:
a report from the ESMO/EAPC Opioid Policy
Initiative. Ann Oncol. 2010;21(3):615-626. doi:10.
1093/annonc/mdp581
11. Cleary J, Gelband H,Wagner J. Cancer pain
relief. In: Gelband H, Jha P, Sankaranarayan R,
Horton S, eds. Cancer: Disease Control Priorities. Vol
3. 3rd ed. Washington, DC: The International Bank
for Reconstruction and Development/The World
Bank; 2015:chap 9.
12. Seya MJ, Gelders SF, Achara OU, Milani B,
ScholtenWK. A first comparison between the
consumption of and the need for opioid analgesics
at country, regional, and global levels. J Pain Palliat
Care Pharmacother. 2011;25(1):6-18. doi:10.3109/
15360288.2010.536307
13. Unger JM,CookE, Tai E, BleyerA. The role of
clinical trial participation in cancer research: barriers,
evidence, and strategies.AmSocClinOncol EducBook.
2016;35:185-198. doi:10.1200/EDBK_156686
14. Murthy VH, Krumholz HM, Gross CP.
Participation in cancer clinical trials: race-, sex-,
and age-based disparities. JAMA. 2004;291(22):
2720-2726. doi:10.1001/jama.291.22.2720
15. Unger JM, Gralow JR, Albain KS, Ramsey SD,
Hershman DL. Patient income level and cancer
clinical trial participation: a prospective survey
study. JAMA Oncol. 2016;2(1):137-139. doi:10.1001/
jamaoncol.2015.3924
16. Unger JM, Hershman DL, Albain KS, et al.
Patient income level and cancer clinical trial
participation. J Clin Oncol. 2013;31(5):536-542.
doi:10.1200/JCO.2012.45.4553
17. Kalata P, Martus P, Zettl H, et al; German Rectal
Cancer Study Group. Differences between clinical
trial participants and patients in a population-based
registry: the German Rectal Cancer Study vs. the
Rostock Cancer Registry. Dis Colon Rectum. 2009;
52(3):425-437. doi:10.1007/DCR.0b013e318197d13c
18. JinS,PazdurR,SridharaR.Re-evaluatingeligibility
criteria for oncology clinical trials: analysis of
investigational new drug applications in 2015. J Clin
Oncol. 2017;35(33):3745-3752. doi:10.1200/JCO.2017.
73.4186
19. NussbaumN, George DJ, Abernethy AP, et al.
Patient experience in the treatment of metastatic
castration-resistant prostate cancer: state of the
science. Prostate Cancer Prostatic Dis. 2016;19(2):
111-121. doi:10.1038/pcan.2015.42
20. Small EJ, Higano CS, Kantoff PW,Whitmore JB,
Frohlich MW, Petrylak DP. Time to disease-related
pain and first opioid use in patients with metastatic
castration-resistant prostate cancer treated with
sipuleucel-T. Prostate Cancer Prostatic Dis. 2014;17
(3):259-264. doi:10.1038/pcan.2014.21
21. SolowayMS, Hardeman SW, Hickey D, et al.
Stratification of patients with metastatic prostate
cancer based on extent of disease on initial bone





androgen-independent prostate cancer. J Clin Oncol.
1999;17(3):948-957. doi:10.1200/JCO.1999.17.3.948
23. TheWorldBank.High income. https://data.
worldbank.org/income-level/high-income.Updated
2019.AccessedDecember 12, 2018.




25. Duthey B, ScholtenW. Adequacy of opioid
analgesic consumption at country, global, and
regional levels in 2010, its relationship with
development level, and changes compared with
2006. J Pain SymptomManage. 2014;47(2):283-297.
doi:10.1016/j.jpainsymman.2013.03.015
26. Hastie BA, Gilson AM, Maurer MA, Cleary JF.
An examination of global and regional opioid
consumption trends 1980-2011. J Pain Palliat Care
Pharmacother. 2014;28(3):259-275. doi:10.3109/
15360288.2014.941132
27. Haider A, Zhukovsky DS, Meng YC, et al. Opioid
prescription trends among patients with cancer
referred to outpatient palliative care over a 6-year




amongcancer patients attending apalliative care
clinic. Support CareCancer. 2007;15(12):1407-1412.
doi:10.1007/s00520-007-0253-8
29. Paque K, Elseviers M, Vander Stichele R, et al.
Changes in medication use in a cohort of patients
with advanced cancer: the international multicentre
prospective European palliative care cancer
symptom study. Palliat Med. 2018;32(4):775-785.
doi:10.1177/0269216317746843
30. Sullivan TR, White IR, Salter AB, Ryan P, Lee KJ.
Should multiple imputation be themethod of
choice for handling missing data in randomized
trials? StatMethodsMed Res. 2018;27(9):2610-2626.
doi:10.1177/0962280216683570
Global Variation in Opioid Use in Prostate Cancer Trials Original Investigation Research
jamaoncology.com (Reprinted) JAMAOncology November 2019 Volume 5, Number 11 7/7
© 2019 American Medical Association. All rights reserved.
© 2019 American Medical Association. All rights reserved. 
 
 
Supplementary Online Content 
 
Roydhouse JK, Suzman DL, Menapace LA, et al. Global variation in opioid use in 




eTable. Regional and Income Classification of Countries of Patient Recruitment 
 
 
This supplementary material has been provided by the authors to give readers 

































© 2019 American Medical Association. All rights reserved. 
 
 
eTable. Regional and Income Classification of Countries of Patient Recruitment 
(N=9,670) 
Country^ N (%) of analytic 
population 
Region Income Status* 
Argentina 46 (0.5%) South/Central America High-income 
Australia 823 (8.5%) Oceania High-income 
Austria 55 (0.6%) Western Europe High-income 
Belarus 21 (0.2%) Eastern Europe Not high-income 
Belgium 288 (3.0%) Western Europe High-income 
Brazil 198 (2.0%) South/Central America Not high-income 
Bulgaria 2 (0.02%) Eastern Europe Not high-income 
Canada 692 (7.2%) North America High-income 
Chile 41 (0.4%) South/Central America High-income 
China 147 (1.5%) Asia Not high-income 
Colombia 17 (0.2%) South/Central America Not high-income 
Czech Republic 98 (1.0%) Eastern Europe High-income 
Denmark 199 (2.1%) Western Europe High-income 
Finland 77 (0.8%) Western Europe High-income 
France 885 (9.2%) Western Europe High-income 
Germany 429 (4.4%) Western Europe High-income 
Greece 14 (0.1%) Western Europe High-income 
Hong Kong (SAR) 21 (0.2%) Asia High-income 
Hungary 91 (0.9%) Eastern Europe High-income 
Israel 77 (0.8%) Middle East/Africa High-income 
Italy 202 (2.1%) Western Europe High-income 
Ireland (Rep. of) 14 (0.1%) Western Europe High-income 
Japan 149 (1.5%) Asia High-income 
Korea (Rep. of) 167 (1.7%) Asia High-income 
Lithuania 14 (0.1%) Eastern Europe High-income 
Malaysia 6 (0.1%) Asia Not high-income 
Mexico 74 (0.8%) South/Central America Not high-income 
Netherlands 176 (1.8%) Western Europe High-income 
New Zealand 11 (0.1%) Oceania High-income 
Norway 137 (1.4%) Western Europe High-income 
Peru 38 (0.4%) South/Central America Not high-income 
Poland 218 (2.3%) Eastern Europe High-income 
Portugal 73 (0.8%) Western Europe High-income 
Romania 161 (1.7%) Eastern Europe Not high-income 
Russian Federation 366 (3.8%) Eastern Europe Not high-income 
Singapore 14 (0.1%) Asia High-income 
Slovakia 80 (0.8%) Eastern Europe High-income 
South Africa 60 (0.6%) Middle East/Africa Not high-income 
Spain 423 (4.4%) Western Europe High-income 
Sweden 215 (2.2%) Western Europe High-income 
Taiwan (POC) 24 (0.2%) Asia High-income 
Tunisia 16 (0.2%) Middle East/Africa Not high-income 
Turkey 52 (0.5%) Middle East/Africa Not high-income 
Ukraine 145 (1.5%) Eastern Europe Not high-income 
United Kingdom 953 (9.9%) Western Europe High-income 
United States 1661 (17.2%) North America High-income 
*Based on WorldBank classification of high-income countries; ^Designation of countries follows the 
abbreviations/country names provided in the datasets and/or World Bank website and should not be construed as a 
political statement 
